Brief: Alteogen Enters Into Global License Agreement With A Top Pharmaceutical Company For Use Of Its Hybrozyme Technology

Alteogen

24/06/2020 13:11

June 24 (Reuters) - Alteogen Inc  196170.KQ :
    * ALTEOGEN ENTERS INTO A GLOBAL LICENSE AGREEMENT WITH A TOP
TEN
PHARMACEUTICAL COMPANY FOR USE OF ITS HYBROZYME™ TECHNOLOGY TO
ENABLE SUBCUTANEOUS ADMINISTRATION OF BIOLOGIC PRODUCTS
    * ALTEOGEN INC - WILL RECEIVE AN INITIAL PAYMENT OF USD 16
MILLION
    * ALTEOGEN - ELIGIBLE TO GET ADDITIONAL MILESTONES UPON
TTPC'S
ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY & SALES
MILESTONES, TOTALING $3.865 BILLION
    * ALTEOGEN INC - GRANTED WORLDWIDE RIGHTS FOR TTPC TO
DEVELOP
MULTIPLE PRODUCTS IN COMBINATION WITH ALT-B4
    * ALTEOGEN INC - WILL BE RESPONSIBLE FOR REGULATORY
DEVELOPMENT
AND COMMERCIAL SUPPLY OF ALT-B4

Source text for Eikon:  ID:nBw7D0Znra 
Further company coverage:  196170.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))